Join our daily newsletter At The Bell to receive exclusive market insights
Optiscan Imaging Ltd (ASX:OIL) has commenced a pre-clinical study at a German university to assess the company’s Gen2 real-time imaging capability on GI (gastrointestinal) tract tissue.
Activities to support the study – particularly completion of the first prototype to collect images from the GI tract – have been completed at the research site, the University Medical Centre of the Johannes Gutenberg University in Mainz.
Optiscan CEO and managing director Dr Camile Farah visited Germany in January in preparation for this research, which will focus on using images of the GI tract to analyse the company’s Gen2 technology – particularly its imaging capability when it comes to diagnosing and treating GI diseases, including cancer.
Dr Farah was also on-site to lock in planning for the clinical phase of the trial, which will follow over coming months.
It is hoped this staged process of gathering pre-clinical and then clinical data with this Gen2 prototype will be helpful to engineers working with Optiscan in developing the company’s Gen3 flexible endomicroscope, which will be used in future clinical trials.
Collection of imaging datasets of various disease processes – taken from the current study – is also expected to aid with initiation of AI algorithm development by Optiscan’s CRC-P partner, Monash University.
“We are thrilled to be undertaking this study with the prestigious University Medical Center of Mainz,” Dr Farah said.
“It will be under the leadership of renowned world-leading gastroenterologist Professor Ralph Kiesslich, and represents a major step forward in helping to better understand and manage one of the world’s biggest health issues.
“GI diseases represent a significant global health challenge, affecting millions of lives each year. Early detection and precise intervention are critical, yet traditional diagnostic tools often fall short in providing timely and accurate insights.”
Optiscan shares have been trading at 16 cents.
Join the discussion: See what HotCopper users are saying about Optiscan Imaging and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
